Best Immunotherapy Companies in San Francisco, United States
The 70 best Immunotherapy companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Allogene Therapeutics.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Allogene Therapeutics Developer of chimeric antigen receptor cell therapy to treat cancer | $532M | 25 mo ago | 303 303 → 215 (-29%) · sector median +1% | 2018 | David Chang President and Chief Executive Officer | 414 patents Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies | 3 launchs |
| 2 | Brii Biosciences Developer of biologics to treat hepatitis B infection | $515M | 57 mo ago | 68 68 → 83 (+22%) · sector median +1% | 2018 | Zhi Hong Co-Founder & CEO | 106 patents Antiviral nucleoside analogs/capsid inhibitors and neurosteroid-based CNS therapeutics | — |
| 3 | Stemcentrx Developing antibodies and antibody-drug conjugates (ADCs) to target cancer stem cells. | $500M | 130 mo ago | 147 | 2008 | — | 142 patents Antibody‑drug conjugates targeting cancer antigens (e.g., PTK7, DLL3, EFNA4, claudins). | — |
| 4 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | 224 224 → 233 (+4%) · sector median +1% | 2018 | Stan Riddell Co-Founder | 163 patents Engineering and manufacturing of enhanced CAR‑T cells and cytokine gene therapies | — |
| 5 | Tizona Therapeutics Developer of antibodies to modulate the activity of immunosuppressive cells in the tumor microenvironment | $475M | 71 mo ago | 43 43 → 23 (-47%) · sector median +1% | 2015 | Christine Muchi O'brien Chief Executive Officer | — | — |
| 6 | Pionyr Immuntherapeutics Cancer immunotherapies that target the tumour microenvironment to enhance the body’s antitumour immunity | $352M | 72 mo ago | 64 | 2015 | Sachdev Sidhu Co-Founder | — | — |
| 7 | Sonoma Biotherapeutics Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 58 mo ago | 74 74 → 66 (-11%) · sector median +1% | 2012 | Fred Ramsdell Co-Founder | 54 patents Engineered immune cell therapies using chimeric antigen receptors and cytokine receptor designs | 1 job opening |
| 8 | Asher Biotherapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $218M | 26 mo ago | 48 | 2019 | Ivana Djuretic Founder | 78 patents Patents concentrated in chemistry & materials | — |
| 9 | Vir Biotechnology Developer of therapeutics for the treatment of infectious diseases | $216M | 73 mo ago | 417 417 → 471 (+13%) · sector median +1% | 2017 | Klaus Frueh Co-Founder | 423 patents Broadly neutralizing antiviral antibodies and combination therapies for hepatitis B and respiratory viruses | — |
| 10 | FibroGen Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible… | $215M | 138 mo ago | 592 | 1993 | Thane Wettig Chief Executive Officer | 748 patents Therapeutics targeting HIF prolyl hydroxylase inhibition and immuno‑modulatory antibodies (galectin‑9, CCR8). | — |
| 11 | Alector Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 94 mo ago | 211 211 → 140 (-34%) · sector median +1% | 2013 | — | 611 patents Therapeutic antibodies targeting neurodegeneration and immune modulation proteins. | — |
| 12 | PACT Pharma Develope of synthetic neo-antigen targeting TILs through T cell isolation platform | $200M | 77 mo ago | 185 | 2016 | — | — | — |
| 13 | Attralus Developer of drugs for the treatment of Amyloid diseases | $197M | 28 mo ago | 23 | 2019 | Jonathan Wall Co-Founder | 50 patents Engineered Fc‑fusion and antibody‑peptide biologics for amyloid disease therapy | — |
| 14 | Spyre Therapeutics Developer of monoclonal antibody therapeutics for inflammatory bowel disease | $180M | 30 mo ago | 30 | 2023 | Cameron Turtle CEO | — | 1 award |
| 15 | ESCAPE Bio Developer of therapeutic solutions for treating genetic neurodegenerative diseases | $167M | 69 mo ago | 39 | 2015 | Julie Smith CEO | — | — |
| 16 | Ideaya Biosciences Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 70 mo ago | 124 124 → 266 (+115%) · sector median +1% | 2015 | Joshua Bleharski Chief Financial Officer | 311 patents Targeted small‑molecule cancer therapies focusing on PKC, MAT2A, and splicing inhibition | 1 launch · 1 partnership |
| 17 | Five Prime Therapeutics Developer of antibodies for the treatment of cancer and inflammatory diseases | $154M | 101 mo ago | 69 | 2002 | — | 971 patents Therapeutic antibodies and fusion proteins for oncology and kidney disease targets | — |
| 18 | True North Therapeutics Antibodies that selectively targets the Classical pathway of the Complement system to treat rare diseases. | $142M | 116 mo ago | 18 | 2013 | — | — | — |
| 19 | Nura Bio Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines | $141M | 21 mo ago | 25 | 2018 | Marc Freeman Co-Founder | — | — |
| 20 | Amphivena Therapeutics Premier website for live soccer streaming, offering diverse football content | $128M | 81 mo ago | 17 | 2012 | — | — | — |
| 21 | Walking Fish Therapeutics Developer of cell-based therapeutic solutions for treating cancer & immunological disorders | $123M | 52 mo ago | 37 | 2019 | Seenu Kothakota Co-Founder | — | — |
| 22 | Ouro Medicines Developer of therapeutics for people living with chronic immune-mediated diseases | $120M | 17 mo ago | — | 2024 | Jaideep Dudani CEO | — | — |
| 23 | Nkarta Therapeutics Developer of cell therapies for the treatment of cancer | $114M | 81 mo ago | 163 163 → 157 (-4%) · sector median +1% | 2015 | — | — | — |
| 24 | Iconic Therapeutics Immunoconjugate proteins that trigger the immune system to destroy invader cells to treat AMD and ocular… | $105M | 85 mo ago | 4 | 2002 | Kirk Dornbush Co-Founder | — | — |
| 25 | Firefly Bio Developer of antibody drug conjugates for the treatment of cancer | $94M | 30 mo ago | — | 2022 | John Flygare Co-Founder and CSO | — | — |
| 26 | STAR Therapeutics Developer of antibody therapies for multiple diseases 40Funding top 21%Moat top 42%Talent bottom 49%News bottom 45% All 6 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Newsbottom 45% Marketbottom 42% Globalbottom 38% Funding: Raised $90.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $90M | 8 mo ago | 43 | 2018 | Adam Rosenthal Founder & CEO | — | — |
| 27 | Principia Biopharma Developer of small-molecule drugs targeting autoimmune diseases and cancer | $90M | 130 mo ago | 122 | 2011 | — | 717 patents Small-molecule BTK and immunoproteasome inhibitors for autoimmune and thrombotic therapies | — |
| 28 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 3 mo ago | 19 | 2011 | Stephen B Chief Executive Officer | — | — |
| 29 | Rigel Developer of drugs for hematologic disorders, cancer, and rare immune disease | $76M | 64 mo ago | 147 147 → 292 (+99%) · sector median +1% | 1996 | Raul Rodriguez President and CEO | 6 patents Patents concentrated in computing, sensing & instrumentation | 3 partnerships |
| 30 | IgGenix Developer of therapeutic solutions for treating food allergy | $75M | 40 mo ago | 12 | 2019 | Stephen Quake Co-Founder | 36 patents Peptide-based diagnostics and therapeutics targeting allergic disease prediction and treatment | — |
| 31 | Vaxart Developer of therapeutic solutions for treating multiple infectious diseases | $58M | 137 mo ago | 110 110 → 108 (-2%) · sector median +1% | 2004 | Steve Lo Chief Executive Officer | 104 patents Patents concentrated in health & consumer products | — |
| 32 | CERo Therapeutics Developer of platforms for cellular immunotherapy | $56M | 14 mo ago | 15 15 → 16 (+7%) · sector median +1% | 2016 | — | — | — |
| 33 | Jennerex Biotherapeutics Developing oncolytic immunotherapies for solid tumors, targeting cancer through diverse mechanisms | $47M | 157 mo ago | 7 | 2003 | — | 12 patents Oncolytic vaccinia virus immunotherapies expressing GM‑CSF for systemic cancer treatment | — |
| 34 | Sequenta Immune medicine company decoding the adaptive immune system for disease treatment | $43M | 140 mo ago | 58 | 2008 | Thomas Willis Co-Founder | 139 patents Immune repertoire sequencing and clonotype analysis for diagnostic biomarker detection | — |
| 35 | Tolerion Developer of therapeutics to treat autoimmune diseases | $43M | 76 mo ago | 12 | 2001 | John Statham Founder | 17 patents Stabilized DNA therapeutics and immunomodulatory treatments for type 1 diabetes | — |
| 36 | Soteria Biotherapeutics Developer of small molecule-based therapeutic solutions for treating cancer | $42M | 61 mo ago | 23 | 2018 | Zachary Hill Co-Founder | 10 patents Chemically inducible dimerization platforms for bispecific T‑cell engager and Fc fusion therapeutics | — |
| 37 | GigaGen Developer of T-cell and antibody-based therapeutics | $36M | 101 mo ago | 36 | 2011 | — | 198 patents Engineering recombinant polyclonal therapeutic proteins and immune‑repertoire fusion constructs. | — |
| 38 | Cell Design Labs Developer of CAR T-cell-based immunotherapies for cancer and other devastating diseases | $34M | 120 mo ago | 8 | 2015 | — | 80 patents Design of engineered chimeric immune receptors and membrane-targeted polypeptides | — |
| 39 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | 2011 | — | 26 patents Therapeutic anti‑integrin β1 antibodies for oncology applications | — |
| 40 | cTRL Therapeutics Developer of therapeutics for solid tumor treatments | $19M | 20 mo ago | — | 2022 | Shana Kelley Founder | — | — |
| 41 | Chimera Developing safe and effective CAR T cell therapeutics, using next generation control technology | $17M | 41 mo ago | 20 | 2015 | — | 16 patents Modular, removable lighting fixtures with interchangeable support‑rod mounting systems | — |
| 42 | Shennon Biotechnologies Developer of immune cell therapies against solid tumors and autoimmune disease | $13M | 39 mo ago | 8 | 2021 | Li Sun Founder/CEO | 10 patents Engineered immune cell therapies and high-throughput microfluidic cell interaction screening | 4 job openings · 1 internship |
| 43 | Xalud Therapeutics Gene therapy company restoring immune balance to treat chronic inflammation | $12M | 74 mo ago | 19 | 2009 | — | — | — |
| 44 | ImmuneBridge Developer of allogeneic cellular medicines to treat cancer | $12M | 15 mo ago | 4 | 2018 | Jesse Cotari Co-Founder | 10 patents Patents concentrated in health & consumer products | — |
| 45 | Infinimmune Developer of antibody-based drugs to treat various diseases | $12M | 42 mo ago | 10 | 2022 | Michael Gibbons Co-Founder | — | — |
| 46 | Trellis Bioscience Human antibodies against infectious diseases and cancer | $10M | 14 mo ago | 6 | 1998 | Stefan Ryser President & CEO | 170 patents Antibody-based therapeutics and vaccines targeting RSV and influenza viral proteins. | — |
| 47 | Serotiny Provider of drug research and development services for cell & gene therapies | $7M | 39 mo ago | 12 | 2009 | — | 12 patents Engineered conditional immune cell receptors for targeted immunotherapy applications. | — |
| 48 | Flow Pharma Developer of immunotherapy platform for infectious disease prevention and cancer therapy | $4M | 22 mo ago | 18 | 2002 | Reid Rubsamen Founder & CEO | — | — |
| 49 | GigaMune Developing in vivo cell therapies for cancer and inherited blood disorders | $2M | 14 mo ago | 3 | 2017 | David Johnson Founder & CEO | 26 patents Engineering viral vectors and gene‑editing nucleases for therapeutic cell and vaccine development | — |
| 50 | Kopra Bio Developer of immunotherapies for cancer treatment | $500K | 24 mo ago | — | 2024 | Andrew Bartynski Co-Founder & CEO | — | — |
Top 12 Immunotherapy companies in San Francisco
#1
Public · San Francisco, California · founded 2011 · 19 employees$88.2Mraised▾
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.
- Mar 2026Post IPO$6M
- Mar 2026Post IPO$2M
- Feb 2020Series B$83.2M
- 2015Series A—
#2
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
#3
Public · San Francisco, California · founded 2018 · 224 employees$493Mraised▾
Developer of CAR- T therapy for cancer treatment. The lead CAR program LYL797is developed for the treatment of ROR1+ non-small cell lung cancer and triple-negative breast cancer. Another candidate LYL845 is an autologous TIL therapy for the treatment of multiple solid tumors.
- Jul 2025Post IPO$100M
- Mar 2020Series C$493M
- 2018Seed—
#4
Series D · San Francisco, California · founded 2018 · 43 employees$90Mraised▾
Developer of antibody therapies for multiple diseases. The company is developing antibody drug discovery to generate drug programs that target multiple diseases with a single therapy. Its lead candidate ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders. The company is addressing drugs for immunology, immuno-oncology, and rare hematologic diseases.
- Sep 2025Series D$125M
- Sep 2023Series C$90M
#5
Public · San Francisco, California · founded 2016 · 15 employees$56.1Mraised▾
CERO Therapeutics is developing platforms for cellular immunotherapy. It has developed a hybrid platform that integrates innate and adaptive programs to eliminate the disease. The company has not disclosed the details of its platform as of May 2019.
- Apr 2025Post IPO$5M
- Sep 2024Post IPO$1.2M
- Feb 2024Series A$10.2M
- Nov 2019Series A$43.2M
#6
Acquired · San Francisco, California · founded 2024$120Mraised▾
Developer of therapeutics for people living with chronic immune-mediated diseases. It offers a lead therapeutic candidate OM336 targeting B cell biology for the treatment of multiple myeloma and immune-mediated diseases.
- Jan 2025Series A$120M
#7
Series A · San Francisco, California · founded 2018 · 25 employees$141Mraised▾
NUraBio provides a solution for the diagnosis of a neurological disorder and neuroprotective medicines. The company targets the axonal degeneration and neuroimmune regulation for treating neurological disorders. It also argeting neuron-intrinsic mechanisms and the neuron-glia axis. The lead candidate of the company is small molecule-based SARM1 which is an axon-intrinsic metabolic sensor and regulator with putative immune function. The company also offers tools like x-ray crystallography, cryo-EM, and biophysical platforms for drug discovery, along with genetic screening and biomarker platforms for the identification of translatable biomarkers.
- Sep 2024Series A$68M
- Jul 2020Series A$73M
#8
Public · San Francisco, California · founded 2018 · 303 employees$531.8Mraised▾
Developer of chimeric antigen receptor cell therapy to treat cancer. The lead candidate of the company ALLO-501A targets CD-19 in refractory non-Hodgkin lymphoma. Other drug candidates include ALLO-316 and ALLO-647 for hematological malignancies and solid tumors.
- Apr 2024Grant (prize money)$15M
- Sep 2018Series A$120M
- Jun 2018Grant (prize money)$58.3K
- Apr 2018Series A$411.8M
#9
Series C · San Francisco, California · founded 1998 · 6 employees$10.2Mraised▾
Trellis Bioscience is a biotech company that develops human antibodies against infectious diseases and cancer. The company's technology platform, CellSpot, identifies B-cells that produce desirable human antibodies for therapeutic use. The company licensed a pre-IND stage anti-RSV mAb to MedImmune in 2009 and licensed its influenza A and B program to ContraFect in 2014. The company's current lead program is focused on pandemic influenza. The company also has discovered antibodies against following immuno-oncology targets: TIM-3 (T-cell immunoglobulin and mucin domain 3), LAG-3 (Lymphocyte-activation gene 3), KIR (Killer cell immunoglobulin-like receptors), CEACAM (Carcino-Ebryonic Antigen) and B7-H3.
- Apr 2025Grant (prize money)$297.9K
- Sep 2020Grant (prize money)$3M
- Jan 2020Grant (prize money)$3.2M
- Feb 2016Grant (prize money)$5.8M
#10
Series C · San Francisco, California · founded 2019 · 48 employees$218.5Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. The company's portfolio includes AB821, a CD8-targeted IL-21 immunotherapy, and early-stage programs targeting CAR-T cells, myeloid cells and CD4+ T cells.
- Apr 2024Series C$55M
- Sep 2021Series B$108M
- Mar 2021Series A$55M
- Aug 2019Seed$125K
#11
Seed · San Francisco, California · founded 2018 · 4 employees$12Mraised▾
Developer of allogeneic cellular medicines to treat cancer. The company is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies, to make curative cancer therapies accessible to everyone.
- Mar 2025Seed$7.7M
- Jan 2023Seed$12M
#12
Series B · San Francisco, California · founded 2019 · 23 employees$197Mraised▾
Developer of drugs for the treatment of Amyloid diseases. The lead product AT-01 uses a polybasic peptide radiotracer technology and helps in the diagnostic of amyloid diseases. Other products include AT-02 & AT-03 which are PAR-SAP components that mediate binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.
- Feb 2024Series B$56M
- Sep 2021Series B$116M
- Sep 2020Series A$25M
- Dec 2019Conventional Debt$175K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.